Osimertinib plus Savolitinib in pts with EGFRm MET-Amplified/Overexpressed NSCLC: Phase Ib TATTON Parts B and D Final Analysis

被引：7
|
作者：
Han, J. [1 ]
Sequist, L. [2 ]
Ahn, M. [3 ]
Cho, B. C. [4 ]
Yu, H. [5 ]
Kim, S. [6 ]
Yang, J. C. [7 ]
Lee, J. S. [8 ]
Su, W. [9 ]
Kowalski, D. M. [10 ]
Orlov, S. [11 ]
Cantarini, M. [12 ]
Ren, S. [13 ]
Frewer, P. [14 ]
Ou, X. [14 ]
Janne, P. [15 ]
机构：
[1] Natl Canc Ctr, Res Inst & Hosp, Ctr Lung Canc, Goyang, South Africa
[2] Massachusetts Gen Hosp, Dept Med, Boston, MA 02114 USA
[3] Sungkyunkwan Univ, Samsung Med Ctr, Sch Med, Seoul, South Korea
[4] Yonsei Canc Ctr, Dept Med, Seoul, South Korea
[5] Mem Sloan Kettering Canc Ctr, Dept Med Oncol, 1275 York Ave, New York, NY 10021 USA
[6] Univ Uslan, Dept Oncol, Asan Med Ctr, Coll Med, Seoul, South Korea
[7] Natl Taiwan Univ Canc Ctr, Dept Oncol, Taipei, Taiwan
[8] Seoul Natl Univ, Dept Internal Med, Bundang Hosp, Seoul, South Korea
[9] Natl Cheng Kung Univ Hosp, Dept Internal Med, Tainan, Taiwan
[10] Maria Sklodowska Curie Natl Res Inst Oncol, Dept Lung Canc & Thorac Oncol, Warsaw, Poland
[11] Bioeq Llc, St Petersburg, Russia
[12] Astrazeneca, Oncol R&D, Cambridge, England
[13] Astrazeneca, Clin Pharmacol & Quantitat Pharmacol, Gaithersburg, MD USA
[14] Astrazeneca, Oncol Biometr Oncol R&D, Cambridge, England
[15] Dana Faber Canc Inst, Dept Med Oncol, Boston, MA USA
来源：
JOURNAL OF THORACIC ONCOLOGY | 2021年 / 16卷 / 03期
关键词：
non-small cell lung cancer; Savolitinib; osimertinib;
D O I：
10.1016/j.jtho.2021.01.146
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
FP14.03
引用
收藏
页码：S227 / S228
页数：2
相关论文
共 23 条
  • [1] The effect of savolitinib plus osimertinib on ctDNA clearance in patients with EGFR mutation positive (EGFRm) MET-amplified NSCLC in the TATTON study
    Hartmaier, Ryan
    Han, Ji-Youn
    Ahn, Myung-Ju
    Cho, Byoung Chul
    Cantarini, Mireille
    Frewer, Paul
    Frigault, Melanie M.
    Oxnard, Geoffrey
    [J]. CANCER RESEARCH, 2020, 80 (16)
  • [2] TATTON Ph Ib Expansion Cohort: Osimertinib plus Savolitinib for Pts with EGFR-Mutant MET-Amplified NSCLC after Progression on Prior EGFR-TKI
    Ahn, M.
    Han, J.
    Sequist, L.
    Cho, B. C.
    Lee, J. S.
    Kim, S.
    Su, W.
    Tsai, C.
    Yang, J. C.
    Yu, H.
    Horn, L.
    Lee, K.
    Haddad, V.
    Frigault, M.
    Ahmed, G.
    Yang, L.
    Ghiorghiu, D.
    Oxnard, G.
    [J]. JOURNAL OF THORACIC ONCOLOGY, 2017, 12 (11) : S1768 - S1768
  • [3] Phase Ib study of savolitinib ± osimertinib in Japanese patients (pts) with advanced solid malignancies & EGFRm NSCLC: TATTON part C
    Hirashima, T.
    Yoh, K.
    Saka, H.
    Kurata, T.
    Ohe, Y.
    Hida, T.
    Mellemgaard, A.
    Verheijen, R. B.
    Ou, X.
    Hayama, M.
    Sugibayashi, K.
    Oxnard, G.
    [J]. ANNALS OF ONCOLOGY, 2020, 31 : S1393 - S1393
  • [4] Savolitinib (savo) plus osimertinib (osi) vs savo plus placebo (PBO) in patients (pts) with EGFR-mutated (EGFRm), MET-amplified advanced NSCLC with progression on osi
    Yang, James Chih-Hsin
    Chen, Yuh-Min
    Batra, Ullas
    Do, Kien
    Sitthideatphaiboon, Piyada
    Danchaivijitr, Pongwut
    Lee, Kang-Yun
    Chindaprasirt, Jarin
    Yang, Cheng-Ta
    Chang, Gee-Chen
    Charoentum, Chaiyut
    Ungtrakul, Teerapat
    Moran, Juan Ignacio Hernandez
    Hartmaier, Ryan
    Haskins, Matthew
    Xu, Wanning
    Riess, Jonathan W.
    [J]. CANCER RESEARCH, 2024, 84 (07)
  • [5] Acquired resistance in patients with EGFRm NSCLC following treatment with osimertinib plus savolitinib in the Ph1b TATTON study Parts B and D.
    Markovets, Aleksandra
    Han, Ji-Youn
    Cho, Byoung Chul
    Cantarini, Mireille
    Janne, Pasi A.
    Hartmaier, Ryan
    [J]. CANCER RESEARCH, 2021, 81 (13)
  • [6] A Phase Ib Trial of Savolitinib plus Gefitinib for Chinese Patients with EGFR-Mutant MET-Amplified Advanced NSCLC
    Yang, J. -
    Fang, J.
    Shu, Y.
    Chang, J.
    Chen, G.
    He, J.
    Li, W.
    Liu, X.
    Yang, N.
    Zhou, C.
    Huang, J.
    Yang, L.
    Handzel, A.
    Frigault, M.
    Ahmed, G.
    Egile, C.
    Morgan, S.
    Wu, Y.
    [J]. JOURNAL OF THORACIC ONCOLOGY, 2017, 12 (11) : S1769 - S1769
  • [7] Baseline and on-treatment plasma-based genomics as a predictor of outcome in SAVANNAH: Savolitinib plus osimertinib in EGFRm MET overexpressed/amplified NSCLC post-osimertinib
    Hartmaier, Ryan James
    Markovets, Aleksandra
    Xu, Wanning
    Baczynska, Agata
    Todd, Alexander
    Ahn, Myung-Ju
    [J]. CANCER RESEARCH, 2023, 83 (08)
  • [8] TATTON Phase Ib expansion cohort: Osimertinib plus savolitinib for patients (pts) with EGFR-mutant, MET-amplified NSCLC after progression on prior third-generation epidermal growth factor receptor (EGFR) tyrosine kinase inhibitor (TKI)
    Sequist, Lecia V.
    Lee, Jong Seok
    Han, Ji-Youn
    Su, Wu-Chou
    Yang, James Chih-Hsin
    Yu, Helena
    Ottesen, Lone H.
    Verheijen, Remy B.
    Mellemgaard, Anders
    Wessen, Jonathan
    Oxnard, Geoffrey
    Cho, Byoung Chul
    [J]. CANCER RESEARCH, 2019, 79 (13)
  • [9] TATTON Phase Ib expansion cohort: Osimertinib plus savolitinib for patients (pts) with EGFR-mutant, MET-amplified NSCLC after progression on prior first/second-generation epidermal growth factor receptor (EGFR) tyrosine kinase inhibitor (TKI)
    Yu, Helena
    Ahn, Myung-Ju
    Kim, Sang-We
    Cho, Byoung Chul
    Sequist, Lecia
    Orlov, Sergey
    Ottesen, Lone H.
    Verheijen, Remy B.
    Mellemgaard, Anders
    Wessen, Jonathan
    Han, Ji-Youn
    [J]. CANCER RESEARCH, 2019, 79 (13)
  • [10] MET Biomarker-based Preliminary Efficacy Analysis in SAVANNAH: savolitinib plus osimertinib in EGFRm NSCLC Post-Osimertinib
    Ahn, M-J.
    De Marinis, F.
    Bonanno, L.
    Cho, B. C.
    Kim, T. -M.
    Cheng, S.
    Novello, S.
    Proto, C.
    Kim, S. -W.
    Lee, J. S.
    Metro, G.
    Yang, J. C.
    Xu, W.
    Hartmaier, R.
    Telaranta-Keerie, A.
    Poole, L.
    Sequist, L.
    [J]. JOURNAL OF THORACIC ONCOLOGY, 2022, 17 (09) : S469 - S470
123